| Not Yet Recruiting | "Pregnancy and Viral Infections: Impact on Pregnant Women and Their Children. French Prospective Cohort" NCT07412977 | ANRS, Emerging Infectious Diseases | — |
| Not Yet Recruiting | Hepatitis B and C Within the Chinese Community in Milan NCT07241962 | IRCCS Ospedale San Raffaele | — |
| Recruiting | Drug-Drug Intercations and Direct Acting Antiviral Agents Against HCV NCT06928259 | University of Seville | — |
| Not Yet Recruiting | The Epidemic Status and Development Trend of Hepatitis C Virus Infection in Pregnant Women in Xi'an NCT06952036 | First Affiliated Hospital Xi'an Jiaotong University | — |
| Active Not Recruiting | Study of DAA Treatment for Children and Adolescents With Active HCV Infection in Cambodia NCT05992077 | ANRS, Emerging Infectious Diseases | N/A |
| Active Not Recruiting | APPROACH 2.0: HIV, HCV and Syphilis Testing Through Pharmacies NCT05534633 | Memorial University of Newfoundland | N/A |
| Withdrawn | Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects NCT04309734 | Atea Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Withdrawn | Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations (ECLIPSE) NCT04235049 | University of Maryland, Baltimore | Phase 4 |
| Completed | A Community-based Intervention Among Active Drug Users in Montpellier NCT04008927 | ANRS, Emerging Infectious Diseases | N/A |
| Completed | Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE) NCT04134767 | April M Young | N/A |
| Unknown | HIV and HCV Infections in 2 Communes From the Battambang Province, Cambodia: Prevalence Rates, Viral Strains, NCT04044586 | ANRS, Emerging Infectious Diseases | — |
| Completed | Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection NCT04019717 | Atea Pharmaceuticals, Inc. | Phase 2 |
| Withdrawn | Triple or Quadruple Combination DAAs Treatment for Subjects With HCV GT 1b Infection NCT03794258 | Humanity & Health Medical Group Limited | Phase 2 |
| Completed | Addressing the Cascade of Care in Vulnerable Populations With Poor Access to Healthcare in Madrid NCT04062253 | Hospital Universitario Infanta Leonor | — |
| Unknown | Role OF OCT-A TO Detect Possible Retinal Vascular Complications of Sofosbuvir in Patients With Hepatitis C NCT04159246 | Mohamed Saad | — |
| Completed | Evaluation of Safety, Tolerability, and Immunogenicity Study of GLS-6150 in Healthy Volunteers and in Persons NCT03674125 | GeneOne Life Science, Inc. | Phase 1 |
| Completed | Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of SH229 in Patients With HCV Infection NCT03588923 | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Phase 1 |
| Unknown | PK of SOF/LED in HCV - Infected Adolescents With Haematological Disorders NCT04353986 | Ain Shams University | Phase 3 |
| Unknown | Chronic Hepatitis C in Chronic Hemodialysis Recipients - An Observational Study NCT03461250 | Asociacion para el Estudio del Higado | — |
| Completed | Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079) NCT03379506 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Sovaldi-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical Practice NCT02783976 | Gilead Sciences | — |
| Completed | Changes in Cognition in HCV Patients After Virus Eradication With Direct Antiviral Agents NCT03508115 | Corporacion Parc Tauli | — |
| Completed | Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Partic NCT02707601 | Gilead Sciences | Phase 3 |
| Completed | Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a NCT02533427 | Gilead Sciences | Phase 1 |
| Completed | Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment NCT02402452 | Gilead Sciences | Phase 1 |
| Completed | Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairm NCT02397707 | Gilead Sciences | Phase 1 |
| Completed | Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Participants With Chronic Genotype 1 HCV Who Parti NCT01987453 | Gilead Sciences | Phase 2 |
| Completed | Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency NCT01958281 | Gilead Sciences | Phase 2 |
| Completed | Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chr NCT01965535 | Gilead Sciences | Phase 2 |
| Completed | Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiti NCT01463956 | French National Agency for Research on AIDS and Viral Hepatitis | Phase 2 |
| Unknown | Influence of Nevirapine on HCV Viral Load NCT01277627 | Valme University Hospital | N/A |
| Completed | Study of ABT-267 in Both Healthy Volunteers and Hepatitis C Virus (HCV) Genotype 1 Infected Subjects NCT01181427 | Abbott | Phase 1 |
| Completed | A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis NCT01193478 | Gilead Sciences | Phase 1 |
| Terminated | Study in Hepatitis C Virus (HCV) Infected Patients Undergoing Liver Transplantation to Evaluate a Human Monocl NCT01121185 | MassBiologics | Phase 2 |
| Completed | Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patien NCT01072695 | Gilead Sciences | Phase 2 |
| Completed | A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM NCT00959699 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon a NCT00978497 | Hoffmann-La Roche | Phase 2 |
| Completed | Study in Healthy Adults to Evaluate Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir NCT00931281 | Abbott | Phase 1 |
| Completed | A Pilot Study of the Grapefruit Flavonoid Naringenin for HCV Infection NCT01091077 | Massachusetts General Hospital | Phase 1 |
| Completed | Study in Healthy Adults to Evaluate Effect of Food on Pharmacokinetics, Safety and Tolerability of ABT-450 Wit NCT00909311 | Abbott | Phase 1 |
| Terminated | Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus Infecti NCT00874796 | Gilead Sciences | Phase 2 |
| Completed | A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of the ABT-333 Ta NCT00909636 | Abbott | Phase 1 |
| Completed | Bioavailability of ABT-333 Tablet Versus First in Human (FIH) Capsule Formulation and Safety, Tolerability and NCT00895102 | Abbott | Phase 1 |
| Completed | A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Multip NCT00890318 | Abbott | Phase 1 |
| Completed | Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without Ritonavir to Treat Hepatitis C V NCT00850044 | AbbVie | Phase 1 |
| Completed | Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Al NCT00743795 | Gilead Sciences | Phase 2 |
| Completed | A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses NCT00768690 | Abbott | Phase 1 |
| Completed | A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received NCT00726882 | AbbVie (prior sponsor, Abbott) | Phase 2 |
| Completed | Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected Subjects NCT00696904 | AbbVie | Phase 1 |
| Completed | Study of ANA773 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) to Assess Safety, Tolerability NCT01211626 | Hoffmann-La Roche | Phase 1 |
| Completed | Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCV NCT00725803 | Gilead Sciences | Phase 2 |
| Completed | Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C NCT00623649 | Vertex Pharmaceuticals Incorporated | Phase 1 |
| Terminated | A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Pa NCT00401947 | Alexion Pharmaceuticals, Inc. | Phase 2 |
| Unknown | Study of the Role of Dendritic Cells in the Recurrence of Hepatitis C After Liver Transplantation. Analysis of NCT00213707 | University Hospital, Strasbourg, France | — |
| Completed | MMF Influence on HCV Viral Evolution After Liver Transplantation NCT00170131 | Mayo Clinic | — |
| Completed | Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of Hepatitis C Infected Patients NCT00221624 | University Hospital, Bordeaux | Phase 3 |
| Completed | Metabolic Viral Host Properties NCT00893308 | Hadassah Medical Organization | — |